bêta
IA Trial Radar
Un essai clinique correspond aux filtres sélectionnés
Vue en carte
Retour à la recherche

Impact GLP-1 Agonists Following Bariatric Phase IV 150 Microbiome Randomisé

En recrutement
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'étude' pour voir et discuter des informations sur l'étude dans la langue sélectionnée.
L'essai clinique NCT06132477 est conçu pour étudier le traitement de Obésité morbide, Syndrome métabolique, Diabète sucré, Hypertension, Apnée obstructive du sommeil de l'adulte. Il s'agit d'une étude interventionnel en Phase IV. Son statut actuel est : en recrutement. L'étude a débuté le 1 février 2024 et vise à recruter 150 participants. Dirigée par l'Université du Missouri à Columbia, l'étude devrait être terminée d'ici le 1 juillet 2030. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 22 janvier 2026.
Résumé succinct
Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control. Bariat...Afficher plus
Description détaillée
Preliminary Work To date we have established a randomized controlled clinical trial where we are comparing groups of patients with variable lengths of biliopancreatic limb lengths during gastric bypass. VSG patients serve as a control surgical group, and we have gathered both serum and stool in over 200 patients. We have collaborated with both the institutional metagenomics and proteomics centers to process samples a...Afficher plus
Titre officiel

Biometabolic Impact of Continuation of GLP-1 Agonists Following Bariatric

Pathologies
Obésité morbideSyndrome métaboliqueDiabète sucréHypertensionApnée obstructive du sommeil de l'adulte
Publications
Articles scientifiques et travaux de recherche publiés sur cet essai clinique:
Autres identifiants de l'étude
  • 2098885
Numéro NCT
NCT06132477
Date de début (réel)
2024-02-01
Dernière mise à jour publiée
2026-01-22
Date de fin (estimée)
2030-07
Inscription (estimée)
150
Type d'étude
Interventionnel
PHASE
Phase IV
Statut
En recrutement
Mots clés
glp-1 agonist
Morbid Obesity
Bariatric Surgery
Metabolic syndrome
Diabetes Mellitus
Hypertension
Obstructive Sleep Apnea
Objectif principal
Traitement
Méthode d'allocation
Randomisé
Modèle d'intervention
Étude croisée
Masquage
Aucun (ouvert)
Bras / Interventions
Groupe de participants/BrasIntervention/Traitement
Comparateur actifGLP-1 Agonist Group
This cohort will consist of patients undergoing bariatric surgery who are currently receiving a GLP-1 Agonists for weight loss and/or diabetes management, that will be maintained on their preoperative dose of GLP-1 agonist following their bariatric surgery. This includes semaglutide, tirzepitide, among others. The dosage will be variable, but will be the same dose the patient is on prior to the bariatric surgery. Dur...Afficher plus
GLP-1 receptor agonist
Randomized to continue or discontinue GLP-1 receptor agonists after bariatric surgery
Aucune interventionNon-GLP-1 Agonist Group
This cohort will consist of patients undergoing bariatric surgery who are currently receiving a GLP-1 Agonist for weight loss and/or diabetes management that will be required to stop taking their preoperative dose of GLP-1 agonist following their bariatric surgery. Dosage preoperative will be variable based on what the patient is currently taking, as well as the medication being taken.
N/A
Critère principal d'évaluation
Critères d'évaluationDescription de la mesurePériode
Effect of GLP1-RA on weight loss
To investigate the effects of GLP1-RAs on weight loss reflected as change in BMI (kg per meter sq) in patients undergoing metabolic surgery
6 months
Effect of GLP1-RA on circulating bile acids and metabolites
Determine the impact of GLP1-RA on circulating bile acids and other metabolites
6 months
Effector of GLP1-RA on gut microbiome diversity
To determine the impact of GLP1-RAs after bariatric surgery on changes in the gut microbiome
6 months
Effect of GLP1-RA on satiety and hunger
To assess the impact of GLP-1 agonists on satiety and hunger in patients who undergo metabolic surgery. Scale will be a validated scoring system, "Daily Eats Questionnaire," with scores ranging from 0-10, with a 0 indicating no hunger, and 10 indicating extreme hunger
6 months
Effect of GLP1-RA on Glycemic control
HGBA1C levels will be measured at 3 and 6 months after surgery to determine if HGBA1C drops more in patients maintained on GLP1-RA
6 months
Assistant à la participation
Critères d'éligibilité

Âges éligibles
Adulte, Adulte âgé
Âge minimum
18 Years
Sexes éligibles
Tous
  1. Greater than 18 years of age
  2. Participation in care by one of the surgeons at MU Health Care
  3. Undergoing surgical weight loss through the Weight Management and Metabolic Center
  4. Body mass index of 30-80 kg/m2
  5. Meet insurance criteria, as set forth by the patient's insurance policy, to qualify for coverage for weight loss surgery or as a self-pay patient for the weight loss procedure
  6. Planned laparoscopic Roux-en-Y gastric bypass, sleeve gastrectomy, revisional weight loss surgery, or duodenal switch or modification of. If patients are not willing to be randomized they will not be enrolled as randomized but can still participate having samples collected.
  7. Willingness to have blood collected before and after surgical procedure at defined points or at minimum have clinical data collected.
  8. Willingness to have clinical data entered into a prospective database
  9. Additional specimens collected as stated in the protocol will be offered but collection not mandated.

5. Taking a GLP-1 agonist as part of their routine medical care apart from any planned surgical procedure. The current standard of care regarding continuation or discontinuation of GLP-1 agonists has not been established and is at the discretion of members of the patient's medical team but to be included the patient and medical care team must be willing to continue or discontinue the GLP-1 agonist after surgery depending on the randomized group.

  1. Pregnant patient
  2. Desire to not participate
  3. Age less than 18
  4. Patient fails to fulfill insurance mandated criteria and is not interested in paying cash for their procedure
  5. Not taking a GLP-1 agonist as part of standard medical care
  6. Unwilling to follow-up at required postoperative visits
  7. Unwilling to stop GLP-1 agonist if randomized into group to stop GLP-1 agonist or unwilling to continue the GLP-1 agonist if randomized into that respective group. If chooses to continue or discontinue the medication apart from randomization the patient can still participate as a non-randomized participant
University of Missouri-Columbia logoUniversité du Missouri à Columbia94 essais cliniques actifs à explorer
American Society for Metabolic and Bariatric Surgery logoAmerican Society for Metabolic and Bariatric Surgery
Partie responsable de l'étude
Andrew Wheeler, Investigateur principal, Assistant Professor of Surgery, University of Missouri-Columbia
Contact central de l'étude
Contact: Jennifer Randolph, 573-882-4387, [email protected]
1 Centres de l'étude dans 1 pays

Missouri

University of Missouri Hospital, Columbia, Missouri, 65201, United States
Andrew Wheeler, MD, Contact, 573-882-5609, [email protected]
Milot Thaqi, MD, Contact, 7086421788, [email protected]
En recrutement